 | | PRD_000752 | | Name: | CIRCULIN A | | Formula: | C134 H211 N38 O38 S6 | | Definition date: | 2020-08-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000758 | | Name: | THIOPEPTIDE THIOSTREPTON REDUCED AT N-CA BOND OF RESIDUE 14 | | Formula: | C72 H86 N19 O18 S5 | | Description: | THIOSTREPTON IS A HETEROCYCLIC THIOPEPTIDE,
CONSISTING OF FOUR THIAZOLES, ONE THIOZOLINE,
ONE PIPERIDEINE RINGS.
A MODIFIED QUINOLINE, RESIDUE 0, IS LINKED TO
MAIN-CHAIN RESIDUE 1 AND SIDE-CHAIN OF RESIDUE 12.
IN THIS ENTRY RESIDUE 14 WAS CHEMICALLY MODIFIED TO
HAVE A SINGLE BOND N-CA. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000759 | | Name: | THIOPEPTIDE THIOSTREPTON WITH EPIMER FORM OF RESIDUE 9 | | Formula: | C69 H81 N18 O17 S5 | | Description: | THIOSTREPTON IS A HETEROCYCLIC THIOPEPTIDE,
CONSISTING OF FOUR THIAZOLES ONE THIOZOLINE
ONE PIPERIDEINE RINGS.
A MODIFIED QUINOLINE, RESIDUE 0, IS LINKED TO
MAIN-CHAIN RESIDUE 1 AND SIDE-CHAIN OF RESIDUE 12.
IN THIS ENTRY RESIDUE 9 WAS CHEMICALLY MODIFIED
FROM D-CYS TO L-CYS AND RESIDUE 17 (HET DHA)
WAS DELETED. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000760 | | Name: | THIOPEPTIDE THIOSTREPTON OXIDIZED AT CA-CB BOND OF RESIDUE 9 | | Formula: | C69 H79 N18 O17 S5 | | Description: | THIOSTREPTON IS A HETEROCYCLIC THIOPEPTIDE,
CONSISTING OF FOUR THIAZOLES ONE THIOZOLINE
ONE PIPERIDEINE RINGS.
A MODIFIED QUINOLINE LINKED TO MAIN-CHAIN
RESIDUE 1 AND SIDE-CHAIN OF RESIDUE 12.
IN THIS ENTRY RESIDUE 9 WAS CHEMICALLY MODIFIED: THE
CA-CB BOND WAS OXIDIZED FROM SINGLE TO DOUBLE.
RESIDUE 17 (HET DHA) WAS DELETED. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000764 | | Name: | CYCLOSPORIN D, 5,7 mutation | | Formula: | C64 H117 N11 O12 S | | Description: | CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE.
CYCLIZATION IS ACHIEVED BY LINKING THE N- AND
THE C- TERMINI.
CYCLOSPORIN D IS A NATURAL ANALOG OF CYCLOSPORIN A,
OBTAINED IN DIFFERENT NUTRIENT BROTH AND
DIFFERS FROM CYCLOSPORIN IN RESIDUE 6 (ABA6VAL).
THE CYCLOSPORIN D MOLECULE WAS MODIFIED AT
POSITIONS 5 AND 7 TO BE
(6,7-DIHYDRO)4-[(E)-BUTENYL]-4,N-DIMETHYL-THREONINE AND
(2-S-METHYL)-SARCOSINE, RESPECTIVELY. | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000765 | | Name: | CYCLOSPORIN A, 5 mutation | | Formula: | C63 H113 N11 O12 | | Description: | CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE.
CYCLIZATION IS ACHIEVED BY LINKING THE N- AND
THE C- TERMINI.
THE CYCLOSPORIN WAS MODIFIED AT POSITION 5 TO BE
4-[(E)-2-BUTENYL]-4,4,N-TRIMETHYL-L-THREONINE | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000766 | | Name: | CYCLOSPORIN A, 6 mutation | | Formula: | C63 H113 N11 O13 | | Description: | CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE.
CYCLIZATION IS ACHIEVED BY LINKING THE N- AND
THE C- TERMINI.
THE CYCLOSPORIN A MOLECULE WAS MODIFIED AT
POSITION 6 TO BE 2-AMINO-5-HYDROXYPENTANOIC ACID | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000767 | | Name: | CYCLOSPORIN A, 7 mutation | | Formula: | C63 H113 N11 O13 | | Description: | CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE.
CYCLIZATION IS ACHIEVED BY LINKING THE N- AND
THE C- TERMINI.
THE CYCLOSPORIN A WAS MODIFIED AT POSITION 7
TO BE N-METHYL-D-SERINE | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_000768 | | Name: | CYCLOSPORIN A, 8 mutation | | Formula: | C62 H111 N11 O12 | | Description: | CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE.
CYCLIZATION IS ACHIEVED BY LINKING THE N- AND
THE C- TERMINI.
THE CYCLOSPORIN A MOLECULE WAS MODIFIED AT
POSITION 8 TO BE N-METHYL-ISOLEUCINE | | Definition date: | 2012-12-12 | | Last modified: | 2023-09-20 |
|
 | | PRD_002268 | | Name: | Lipid II | | Formula: | C54 H91 N8 O26 P2 | | Definition date: | 2020-08-19 | | Last modified: | 2023-06-11 |
|
 | | PRD_002470 | | Name: | Agrocinopine A (alpha-L-arabinopyranose form) | | Formula: | C17 H31 O18 P | | Description: | phosphodiester of sucrose and L-arabinose | | Definition date: | 2023-05-24 | | Last modified: | 2023-05-24 |
|
 | | PRD_002442 | | Name: | Myxovalargin A | | Formula: | C81 H138 N21 O17 | | Definition date: | 2023-01-18 | | Last modified: | 2023-05-11 |
|
 | | PRD_002419 | | Name: | Cyclomarin A | | Formula: | C56 H82 N8 O11 | | Definition date: | 2023-03-29 | | Last modified: | 2023-03-29 |
|
 | | PRD_002430 | | Name: | Darobactin 9 | | Formula: | C49 H57 N12 O12 | | Definition date: | 2023-01-11 | | Last modified: | 2023-01-11 |
|
 | | PRD_002097 | | Name: | [[[(4S)-5-[[(2S)-1-[[(2S)-5-[[azaniumylidene(azanyl)methyl]amino]-1-oxidanylidene-pentan-2-yl]amino]-3-methyl-1-oxidanylidene-butan-2-yl]amino]-5-oxidanylidene-4-[[(2S)-1-oxidanyl-1-oxidanylidene-3-phenyl-propan-2-yl]carbamoylamino]pentyl]amino]-azanyl-methylidene]azanium | | Formula: | C27 H46 N10 O6 | | Description: | Acts as a reversible inhibitor of serine/cysteine proteases and some trypsin-like serine proteases. | | Definition date: | 2013-08-07 | | Last modified: | 2022-10-20 |
|
 | | PRD_000468 | | Name: | Allosamidin | | Formula: | C25 H42 N4 O14 | | Definition date: | 2015-07-18 | | Last modified: | 2022-03-03 |
|
 | | PRD_002486 | | Name: | N,N-dimethyl-L-valyl-L-leucyl-N-[(3S)-6-{(2S)-2-[([1,1'-biphenyl]-4-yl)methyl]-3-methoxy-5-oxo-2,5-dihydro-1H-pyrrol-1-yl}-6-oxo-1-phenylhexan-3-yl]-L-leucinamide | | Formula: | C49 H67 N5 O6 | | Definition date: | 2022-03-02 | | Last modified: | 2022-03-02 |
|
 | | PRD_002487 | | Name: | N,N-dimethyl-L-valyl-L-leucyl-N-[(3S)-6-{(2S)-2-[(1H-indol-3-yl)methyl]-3-methoxy-5-oxo-2,5-dihydro-1H-pyrrol-1-yl}-6-oxo-1-phenylhexan-3-yl]-L-leucinamide | | Formula: | C45 H64 N6 O6 | | Definition date: | 2022-03-02 | | Last modified: | 2022-03-02 |
|
 | | PRD_000204 | | Name: | Vancomycin | | Formula: | C66 H75 Cl2 N9 O24 | | Description: | VANCOMYCIN IS A TRICYCLIC GLYCOPEPTIDE, GLYCOSYLATED BY A DISACCHARIDE (RESIDUES 8 AND 9) ON RESIDUE 4. | | Definition date: | 2012-12-12 | | Last modified: | 2022-01-06 |
|
 | | PRD_900129 | | Name: | Lewis A antigen, beta anomer | | Formula: | C20 H35 N O15 | | Description: | oligosaccharide with branches | | Definition date: | 2020-08-05 | | Last modified: | 2020-08-05 |
|
 | | PRD_900130 | | Name: | Lewis A antigen, alpha anomer | | Formula: | C20 H35 N O15 | | Description: | oligosaccharide with branches | | Definition date: | 2020-08-05 | | Last modified: | 2020-08-05 |
|
 | | PRD_900131 | | Name: | Blood group A H type 1 antigen, beta anomer | | Formula: | C28 H48 N2 O20 | | Description: | oligosaccharide with branches | | Definition date: | 2020-08-05 | | Last modified: | 2020-08-05 |
|
 | | PRD_900132 | | Name: | Blood group A H type 2 antigen, beta anomer | | Formula: | C28 H48 N2 O20 | | Description: | oligosaccharide with branches | | Definition date: | 2020-08-05 | | Last modified: | 2020-08-05 |
|
 | | PRD_900133 | | Name: | Blood group A H type 2 antigen, alpha anomer | | Formula: | C28 H48 N2 O20 | | Description: | oligosaccharide with branches | | Definition date: | 2020-08-05 | | Last modified: | 2020-08-05 |
|
 | | PRD_900016 | | Name: | CELLOPENTAOSE | | Formula: | C30 H52 O26 | | Description: | oligosaccharide | | Definition date: | 2020-07-29 | | Last modified: | 2020-07-29 |
|
